Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo targets brain tumor fuel in early trial

NCT ID NCT03343197

First seen Feb 20, 2026 · Last updated Jun 18, 2026 · Updated 22 times

Summary

This early-phase study tested two experimental drugs, AG-120 and AG-881, in 49 adults with a recurrent, slow-growing brain tumor (low grade glioma) that has a specific IDH1 gene mutation. The goal was to see if these drugs could lower a substance called 2-HG in the tumor tissue before surgery. The study focused on safety and how the drugs work in the body, not on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • United States, California

    Los Angeles, California, 90024, United States

  • United States, California

    San Francisco, California, 94143, United States

  • United States, Massachusetts

    Boston, Massachusetts, 02215, United States

  • United States, New York

    New York, New York, 10065, United States

  • United States, North Carolina

    Durham, North Carolina, 27710, United States

  • United States, Texas

    Dallas, Texas, 75390, United States

Conditions

The condition(s) this trial relates to.

glioma low grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.